United Therapeutics Corp
UTHR
Market Cap$11.15B
Close$
$364.05
55.5% upside
Current Fair Value
55.5% upsideUndervalued by 55.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.15 Billion |
|---|---|
| Enterprise Value | $8.86 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $19.81 |
| Beta | 0.38 |
| Outstanding Shares | 47,058,545 |
| Avg 30 Day Volume | 508,085 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.32 |
|---|---|
| PEG | 17.6 |
| Price to Sales | 4.78 |
| Price to Book Ratio | 1.84 |
| Enterprise Value to Revenue | 3.8 |
| Enterprise Value to EBIT | 7.47 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
ESG Score
No data
About United Therapeutics Corp
920 employees
CEO: Martine Rothblatt United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...